BPC-157
BPC-157 is the repair peptide – the one people reach for when a tendon, ligament, or gut lining will not close out on its own. It pulls blood flow into the injured area and quiets the inflammation keeping it stuck. Athletes run it for strains and tears that stalled; others run it for gut symptoms, which is where the original research started. It is the most widely used recovery compound in this catalog.
What it does
Injuries that stalled
The main reason people run BPC-157. Tendon, ligament and muscle damage that stopped improving on its own – old strains, nagging elbows and knees, tears that healed badly the first time. The usual approach is a daily subcutaneous injection for 8 to 12 weeks, and people who notice a change tend to notice it in the second or third week. The animal research behind this is deep and consistent; the human research is one small case series.
Sources: Rasic-Markovic A, et al., 2025, Chang CH, et al., 2011
Gut and digestion
BPC-157 was found in human gastric juice, and the gut is where its research began. It is the second most common reason people take it – reflux, general irritation, and getting back to normal after the gut has been through something rough. Same daily schedule as the injury protocol. The gut work is animal-model research; the community use is self-reported.
Sources: Rasic-Markovic A, et al., 2025
Joint pain
The single published human study on BPC-157 put it straight into the knee for chronic pain. Seven of the twelve patients on it alone reported relief lasting more than six months. That was a small chart review rather than a controlled trial, and the injection went into the joint rather than under the skin, which is a different route from the everyday protocol. Worth knowing if joints are why you are here.
Dosing
Community reportedCommunity titration (peptidedosages.com)200 mcg (0.2 mg) to 600 mcg (0.6 mg), once daily
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Weeks 1-2 | 200 mcg (0.2 mg) | once daily | Starting dose1 |
| Weeks 3-4 | 400 mcg (0.4 mg) | once daily | |
| Weeks 5-8+ | 600 mcg (0.6 mg) | once daily | Target/maintenance2 |
- Subcutaneous. Cycle length 8-12 weeks, optional extension to 16 weeks; no specific human maximum-safe-dose has been established in the cited literature.
- Community threads describe a lower everyday baseline of 250-500 mcg, up to 1 mg for stubborn injuries, somewhat below this site's stated 600 mcg ceiling; some users also report the low end awkward to measure on a standard syringe.
Vendor reportedClinic protocol (drrogerscenters.com)250 mcg (0.25 mg) to 500 mcg (0.5 mg)
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Weeks 1-2 | 250 mcg (0.25 mg) | once daily | Starting dose1 |
| After weeks 1-2 | 500 mcg (0.5 mg) | twice daily | Ceiling, if tolerated23 |
- Subcutaneous, often injected near the injured area. The page gives a 4-6 week cycle followed by 2-4 weeks off.
- The page states no end week for this step, only "if tolerated". Its own summary table gives the whole protocol as 250-500 mcg, one to two times daily, over 4-6 weeks. That ceiling sits below the 600 mcg maintenance step in the community schedule above.
- Published by a clinic that sells a BPC-157 blend, and the dosing text links to that product. The page cites no primary literature (its only research link is to Wikipedia) and carries no named author. It states outright that these ranges reflect common practitioner-guided protocols, not medical prescriptions.
Community reportedReported practice pattern (riteaid.com)200-500 mcg (0.2-0.5 mg), once or twice daily
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Whole cycle | 200-500 mcg (0.2-0.5 mg) | once or twice daily | No standard dose exists123 |
- Subcutaneous, sometimes near the injured area, over a four to six week cycle. The page states no washout period. It gives one flat range rather than a week-by-week ladder, so it is reproduced as a single row.
- Rite Aid's consumer health-information page. Alone among the sources here it does not sell BPC-157 and carries no purchase or consultation link. Its four cited papers were each opened and checked, and all four correspond to the claims they are attached to. It is credited to the "Rite Aid Health Team" rather than to a named clinician, which is its one real weakness as a source.
- The page is explicit that no standard dose has been established and that products, routes and concentrations vary. Its 500 mcg ceiling and four-to-six-week cycle match the clinic protocol above, and both sit below the 600 mcg maintenance step and 8-12 week cycle in the community schedule at the top of this section.
Clinical trialIntra-articular injection, chronic knee pain (published case series)4 mg (in 2 mL), single injection
| Timeframe | Dosage | Frequency | Note |
|---|---|---|---|
| Single dose | 4 mg (in 2 mL) | single injection | Intra-articular1 |
- In some cases combined with 6 mg thymosin beta-4. This is a different administration route than the subcutaneous community schedule above and is not interchangeable with it.
Primary structure
GGlyEGluPProPProPProGGlyKLysPProAAlaDAspDAspAAlaGGlyLLeuVVal
Full research
Evidence tier
Early human data only
One retrospective, uncontrolled, unblinded human case series (17 patients, 12 on BPC-157 alone) exists in the published literature, alongside an abandoned, unpublished Phase I safety and pharmacokinetics trial. The overwhelming majority of the evidence base, 35 of 36 studies in the most recent systematic review, is animal or in-vitro.
Identity
| Full name | Body Protection Compound 157 (BPC-157) |
|---|---|
| Class | Synthetic pentadecapeptide, a partial sequence derived from human gastric juice protein BPC |
| Molecular weight | 1419.55 g/mol |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) |
Mechanism of action
Plain language
BPC-157 is proposed to help tissue repair itself faster by improving blood flow to injured areas and calming local inflammation and oxidative stress. Essentially all of this evidence comes from cell and animal studies; the mechanism in humans is inferred, not directly demonstrated.
Technical
The literature most consistently implicates interaction with the nitric oxide system, including upregulation of endothelial nitric oxide synthase-derived nitric oxide and increased expression of VEGFR2 in models of ischemia, both proposed to drive angiogenesis. In tendon-explant models, BPC-157 has been reported to promote fibroblast outgrowth, survival, and migration, an effect attributed to activation of the FAK-paxillin signaling pathway. It has also been reported to upregulate antioxidant-response genes including heme oxygenase-1 and glutathione peroxidase 2. All of these mechanistic claims are proposed rather than established in humans; no human mechanistic, receptor-binding, or target-engagement study has been published.
Sources: Rasic-Markovic A, et al., 2025, Chang CH, et al., 2011
What it’s used for
Human trials, not approved for this use
- The single published human clinical study is a retrospective, uncontrolled, unblinded chart review of intra-articular BPC-157 injection for chronic knee pain (17 patients, 12 on BPC-157 alone). Seven of the 12 patients on BPC-157 alone reported pain relief lasting more than six months, with no control group, no placebo arm, no blinding, and self-reported outcomes. A systematic review found this was 1 of 36 total studies identified on BPC-157 in orthopaedic and sports-medicine contexts; the other 35 were preclinical animal studies, and the review concluded all available clinical evidence is case-series or expert-opinion tier with no clinical safety data found.
Off-label / community use
- Widely used off-label and outside any regulatory framework in fitness, longevity, and injury-recovery communities for soft-tissue injury, tendon and ligament repair, gut and gastrointestinal symptoms, and general recovery. This use is anecdotal, self-reported, and not supported by controlled human data.
Pharmacokinetics
| Human pharmacokinetics, any route |
Not established No citable figure. No published human pharmacokinetic study exists for BPC-157 by any route; the field's own systematic reviews describe human PK data as absent or scanty. |
|---|---|
| Half-life (animal, intravenous, not human-translatable) |
Animal / in-vitro Under 30 minutes in rat and beagle dog; approximately 15.2 minutes in one rat study after intravenous dosing Sources: He L, Feng, 2022 |
| Bioavailability (animal, intramuscular) |
Animal / in-vitro Approximately 14-19% in rats; 45-51% in beagle dogs Sources: He L, Feng, 2022 |
| Time to peak concentration, Tmax (animal) |
Animal / in-vitro Approximately 3 minutes in rats; 6.3-8.7 minutes in dogs across dose-ranging studies Sources: He L, Feng, 2022 |
| Route and disposition (animal) |
Animal / in-vitro Studied intravenously and intramuscularly in rats and dogs; metabolized into small peptide fragments and free amino acids, excreted mainly via urine and bile, with poor blood-brain-barrier penetration. No human PK study by any route has been published. Sources: He L, Feng, 2022 |
Reconstitution
| Vial strength | Most frequently 5 mg lyophilized powder per vial, also sold in 2 mg and 10 mg strengths |
|---|---|
| Diluent | Bacteriostatic water |
| Diluent volume | 2 mL (common vendor convention); an alternative 3 mL reconstitution is also described |
| Concentration | 2.5 mg/mL (5 mg vial in 2 mL); approximately 1.67 mg/mL (5 mg vial in 3 mL) |
Sources: Multiple commercial vendor
Dose calculator
Enter a vial strength, diluent volume, and desired dose to see the resulting concentration, dose volume, and units on a standard U-100 insulin syringe. Nothing entered here is saved, stored, or sent anywhere – the calculation runs only in your browser.
This calculator needs JavaScript. The arithmetic it runs is: concentration = vial strength in mg divided by diluent volume in mL; dose volume in mL = dose in mg divided by concentration; units on a U-100 syringe = dose volume in mL times 100.
Storage and post-reconstitution stability
Unopened storage
Vendors describe lyophilized, unreconstituted BPC-157 as stable refrigerated or frozen, protected from light, prior to reconstitution.
Post-reconstitution stability – Vendor claim
Approximately 28-30 days refrigerated. 2-8C
No citable figure. This figure comes from vendor guidance rather than a published stability study and should be treated as unverified.
Safety
Notable risks
- FDA placed BPC-157 in Category 2 of its 503A bulk drug substances list in September 2023, citing potential immunogenicity, peptide-related impurity and characterization concerns, and the absence of adequate safety information for the proposed routes of administration. Both nominations behind that listing were later withdrawn, and FDA now carries the substance under nominated-but-withdrawn rather than in the active Category 2 table, with the same safety-risk language attached. On 23 July 2026 FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 to the 503A Bulks List, against FDA review staff's own written proposal not to include it. That recommendation is advisory and non-binding: as of 19 August 2026 the 503A Bulks List at 21 CFR 216.23 names six substances and BPC-157 is not among them, and adding it would require notice-and-comment rulemaking that has not taken place.
Sources: U.S. FDA. Bulk, 2023, U.S. FDA. Pharmacy, 2026, 21 CFR 216.23, 2026
- BPC-157 is not scheduled as a controlled substance in the United States but is prohibited at all times in competitive sport under the World Anti-Doping Agency Prohibited List, and is sold almost exclusively as an unregulated research chemical, with manufacturing not subject to pharmaceutical quality oversight.
Sources: USADA. BPC-157: Experimental
- No controlled human safety data exist. Preclinical toxicology in rats and beagle dogs, single-dose intramuscular up to 20 mg/kg in rats and 10 mg/kg in dogs, and repeated 28-day dosing up to 4 mg/kg/day in rats and 2 mg/kg/day in dogs, reported no deaths and no gross abnormalities, but a systematic review of the human literature found no clinical safety data at all.
Sources: Rasic-Markovic A, et al., 2025, Vasireddi N, et al., 2025
- BPC-157's pro-angiogenic activity, VEGFR2 upregulation, is flagged in the literature as a theoretical tumor-growth concern, though mouse cancer-implantation models did not show a marked reduction in tumor size with BPC-157 administration, and did not report data showing it accelerates tumor growth either. A theoretical nitric-oxide-mediated mitochondrial toxicity concern and a theoretical proline-metabolite oxidative-stress concern have also been raised. All are described as mechanistic extrapolations, not observed clinical adverse events.
Sources: Rasic-Markovic A, et al., 2025
Sources
- Rasic-Markovic A, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide, Literature and Patent Review. Pharmaceuticals (Basel) (2025)
- U.S. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, Category 2 update, September 29, 2023 (FDA.gov guidance/advisory-committee-briefing page, not a prescribing label or Federal Register notice) (2023)
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (2011)
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med (2021)
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J (2025)
- He L, Feng D, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol (2022)
- USADA. BPC-157: Experimental Peptide Creates Risk for Athletes (anti-doping authority advisory page, not an FDA or EMA prescribing document)
- Multiple commercial vendor and dosing-guide pages (e.g. peptidedosages.com, formblends.com, thepeptidecatalog.com, biogenixpeptides.com), cited only to describe commercially sold vial strengths and vendor-stated reconstitution and dosing convention, not as evidence for any efficacy or safety claim
- peptidedosages.com, BPC-157 5 mg vial dosage protocol
- Dr. Rogers Centers, BPC-157 Dosage: A Complete Guide (clinic blog page that also sells a BPC-157 blend; no named author, no primary literature cited) (2026)
- Rite Aid, BPC-157 consumer health-information page (retail pharmacy; does not sell BPC-157 and links to no purchase or consultation path; four cited papers independently verified as matching their claims; credited to the Rite Aid Health Team, no named clinician)
- U.S. FDA. Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026, on bulk drug substances nominated for inclusion on the section 503A Bulks List; BPC-157 free base and BPC-157 acetate were agenda items and were each put to a recorded vote. Federal Register notice, docket FDA-2025-N-6895, and FDA's published meeting page and Questions document. FDA review staff's briefing document proposed NOT including either substance. No minutes or transcript published as of 19 August 2026, so the vote tally is not sourced here (2026)
- 21 CFR 216.23, Drug products or categories of drug products that may be compounded under section 503A; the affirmative 503A Bulks List. Checked 19 August 2026: it names six substances and does not include BPC-157 (2026)
This is a research and educational reference, not medical advice. Nothing on this site is a recommendation to use any compound.